Next Phase Newsletter

A venture capital firm based in the US Midwest is focused on early-stage health technology investments with a consumer-focus. The firm is looking for companies with solutions that drive consumer engagement and health accoutability (these do not have to sell D2C, most of their companies do not). The firm manages over $100M in capital with initial investments of $1,000,000 to $5,000,000. The firm is primarily thesis-focused and invests from Seed stage to Series B, with a focus just at or before the A round.

The firm is seeking digital health companies focused on the empowering consumers to be better stewards of their health and their healthcare expenditures. Accordingly, the firm is not interested in technology that solve problems solely within payers and providers, such as billing, care coordination for hospitals, or EHR platforms. The firm is indication agnostic, though has interest in chronic illnesses, social determinants, behavioral health, and personalized care among others.

The firm does not have set management team requirements. The firm will play a very active role post-investment, traditionally by taking board seats, providing key sales introductions, assisting with scaling, hiring, and providing network support.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Canada provides equity capital to portfolio companies and is very flexible in the size of investments it makes, placing a high emphasis on innovation of potential portfolio companies. The firm is currently investing in Canadian companies only, with no set limit on the amount of funds or number of investments.

The firm is looking to invest primarily in innovative green technology as well as biotech therapeutics and medical technology, and is also open to looking at companies in diagnostics and healthcare IT. The firm will consider products of any stage of development, from pre-clinical to phase III as long as the company’s product displays high potential to positively impact the environment or healthcare. In addition, the firm is agnostic to indication and will look at anything that fits in the environment or healthcare sectors.

The firm has taken a board seat in its portfolio companies before, but this is not required by the firm. The companies do not need to have an experienced management team, as innovation is the most important factor that the firm expects from companies. The firm prefers to act as the lead investor, but is open to co-investing with other firms that share the firm’s interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in California invests in primarily early-stage (seed, Series A) companies with truly innovative technologies with a typical investment size of $2-5M per company and can invest as low as $500K. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is seeking innovative technology that is outside traditional biotech. The company is agnostic across life science sectors, including therapeutics, devices, and tools, but will not look at Healthcare IT or digital health technologies. They are interested in therapeutics targeting novel first-in-class targets, and not in biosimilars or repurposed drugs. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A $150 million venture capital fund managed on behalf of a not-for-profit health system makes direct investments in innovative healthcare companies. Typical equity allocations range from $5-8 million over the life of a company. The firm typically co-invests with other VC funds but is also open to leading in a financing round. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission, improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices across the US, Europe and Asia is currently looking to make new investments into biopharmaceutical and medical device companies from its two funds. The firm looks to invest in early stage companies and can provide up to about $17 million to a company over the lifetime of the investment. The firm is most interested in companies based in the US, Canada, Ireland, Singapore and will also consider exceptional opportunities elsewhere in Europe and in Asia. The firm plans to make approximately 8 new investments over the next 6-9 months.

The firm is interested in companies developing either biopharmaceuticals or medical devices. For biopharmaceuticals, the firm is interested in all modalities including small molecules, biologics, and cell and gene therapies. The firm is primarily interested in platform companies with the potential for multiple assets and strongly prefers technologies to be 1st in class or best in class, often originating from breakthrough chemistry or biology discoveries. The firm is looking for companies with assets in discovery through Phase 1 clinical trials. For medical devices, the firm is primarily interested in companies working on devices that have the ability to treat drug-like markets, as well as devices for self-pay markets. The firm is indication-agnostic in both biopharmaceuticals and devices.

The firm can both lead and co-lead investments, with a preference for taking a board seat. The firm prefers working with management teams with positive track records; however, they are open to working with incomplete or non-permanent management teams as well, especially for very early stage opportunities. The investment team has extensive operating experience and deep networks, which they can leverage to support companies as needed.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An asset management group based in China operates a USD fund of $50 million that invests in healthcare and technology startups. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, and healthcare IT products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that have completed a prototype and obtained FDA clearance or are ready for FDA submission. The firm is agnostic to indication areas.

The firm is looking for experienced management teams. The firm can leverage its innovation center to assist with commercialization in the China market. The firm my request distribution rights and board representation post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture arm of a pharmaceutical company seeks to make strategic investments into early-stage companies that are aligned with its parent firm’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. The firm benefits from deep connections into its parent firm’s global research and development centers, and is well placed to nurture innovative pharmaceutical companies and to connect these into the parent organization.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, and CNS. The firm is also interested in breakthrough platforms technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com